|Moderated By: caly -- (Not Moderated) -- Started: 10/30/1997 10:21:00 PM Revision History|
Guided Therapeutics GTHP.OB
Company Website: guidedinc.com
Press Releases: guidedinc.com
SEC Filings: sec.gov
FDA Medical Devices page: fda.gov
Slide presentation from a small cap conference Jan. 2011: guidedinc.com
Shares Outstanding: 49,056,347 as of 10/31/2011
Shares Outstanding: 48,448,685 as of 05/10/2010
Shares Outstanding: 46,480,950 as of 11/01/2010
Shares Outstanding: 42,516,855 as of 07/30/2010
Shares Outstanding: 41,698,396 as of 04/30/2010
Shares Outstanding: 19,614,975 as of 02/25/2010
Shares Outstanding: 17,470,656 as of 11/09/2009
Shares Outstanding: 16,852,823 as of 08/14/2009
Shares Outstanding: 15,998,790 as of 05/22/2009
Shares Outstanding: 11,948,631 as of 04/09/2007
** On February 26, 2010, the Company held a special meeting of stockholders to approve an amendment to the Company’s certificate of incorporation to reclassify the series A convertible preferred stock into common stock and warrants to purchase shares of common stock. As a result, all 242,576 outstanding shares of series A convertible preferred stock and accrued dividends were reclassified into 8,084,139 shares of common stock and warrants to purchase an additional 2,799,327 shares of common stock. Upon this reclassification, approximately $9.1 million in outstanding 2007 Notes was automatically converted into 14.0 million shares of common stock.
Float: 28,292,659 as of 12/01/2010 per the company
Float: 31.21M as of 12/17/2010 per Yahoo
Float: 12.45M as of 3/17/2010 per Yahoo
Warrants and Options
We have issued warrants to purchase our common stock from time to time in connection with certain financing and other arrangements. As of November 30, 2011, there are warrants exercisable for an aggregate of 31,749,910 shares of common stock outstanding. Warrants exercisable for 28,897,934 of these shares have an exercise price of $0.65 per share and expire on March 1, 2013, warrants exercisable for 285,186 of these shares have an exercise price of $1.05 per share and expire on November 20, 2016 and warrants exercisable for 2,560,000 of these shares have an exercise price of $0.01 and expire on March 1, 2013. All outstanding warrant agreements provide for antidilution adjustments in the event of certain mergers, consolidations, reorganizations, recapitalizations, stock dividends, stock splits or other changes in our corporate structure. The shares of common stock to be offered hereby are issuable upon exercise of these warrants.
As of November 30, 2011, we have issued options to purchase a total of 5,700,667 shares of our common stock pursuant to various equity incentive plans, at a weighted average exercise price of $0.53 per share. Recommendations for option grants under our equity incentive plans are made by the compensation committee of our board, subject to ratification by the full board. The compensation committee may issue options with varying vesting schedules, but all options granted pursuant to our equity incentive plans must be exercised within ten years from the date of grant.